Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Top Cited Papers
- 1 February 2016
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 54, 139-148
- https://doi.org/10.1016/j.ejca.2015.11.016
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Immune modulation of the tumor microenvironment for enhancing cancer immunotherapyOncoImmunology, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanomaCancer Management and Research, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- CTLA4 is differentially associated with autoimmune diseases in the Dutch populationHuman Genetics, 2005
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature, 2003